SIMCERE PHARMA (02096.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec25

Xian Shen Pharmaceutical's Subsidiary Signs $1.06 Billion Exclusive License Agreement for ADC Candidate Drug

14:12

Dec24

Simcere and partners' drug Ensituximab Granted Orphan Drug Designation by FDA

11:27

Huatai Securities Maintains Overweight Rating on Simcere Pharmaceutical, Target Price at HKD 19.82

05:36

Dec22

Simcere and Ipsen Reach Exclusive Licensing Agreement for SIM0613

04:12

Dec19

Simcere Pharma Advances Innovation 2.0, Focusing on Original New Drug Development

07:56

Dec15

CITIC Securities Maintains 'Buy' Rating for Xian Shen Pharmaceutical, with a Target Price of HKD 20.16

05:07

Schedules & Filings

Schedules

Filings

Aug21

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 1.962 B, Net Income 330.33 M, EPS 0.1351

Jul14

Distribution Plan(CST)

Cash dividend 0.1748 HKD

Jun19

Distribution Plan(CST)

Cash dividend 0.1748 HKD

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More